Revisiting the Surgical Management of Giant Hepatic Hemangiomas: Enucleation Versus Anatomical Resection?
- PMID: 33994715
- PMCID: PMC8103325
- DOI: 10.1016/j.jceh.2020.09.008
Revisiting the Surgical Management of Giant Hepatic Hemangiomas: Enucleation Versus Anatomical Resection?
Abstract
Background: Resection is rarely indicated in giant hepatic hemangiomas (HHs) that are symptomatic. Enucleation (EN), compared with anatomical resection (AR), is considered the better technique to resect them as EN has been reported to have lower morbidity while conserving the normal liver tissue. But no study has yet clearly established the superiority of EN over AR. In addition, the independent predictors of postoperative morbidity have not been established.
Methods: All consecutive patients operated for HH at two specialized hepatobiliary centers were reviewed. Patient demographics, operative variables, and postoperative outcomes were analyzed and compared between two techniques. Postoperative complications were graded as per Clavien-Dindo classification of surgical complications. The aims of this study were to compare two techniques of HH resection with respect to postoperative outcomes and to identify the risk factors for 90-day major postoperative morbidity and mortality.
Results: A total of 64 patients, including 41 who underwent AR, 22 who underwent EN, and 1 who underwent liver transplantation, were operated for hemangiomas during the study period. Ten patients (9 who were operated for hemangiomas of size ≤4 cm and 1 who underwent transplantation) were excluded. Fifty-four patients, the majority being women (85%), with a median age of 48 years, were operated for giant HH. These patients were classified into two groups based on the technique of resection, namely, EN (22 patients) and AR (32 patients). Both groups were comparable in all aspects except that the number of liver segments resected was significantly more with AR. Postoperative outcomes were similar in both groups. Independent predictors of 90-day major complications including mortality were the use of total vascular exclusion (relative risk [RR]: 2.3, p = 0.028) and duration of surgery >4.5 h (RR: 2.3, p = 0.025).
Conclusion: Both techniques yield similar results with respect to 90-day postoperative morbidity and mortality. The choice of technique should be based on the location of tumor and simplicity of liver resection.
Keywords: AR, anatomical resection; EN, enucleation; HH, giant hepatic hemangioma; POD, postoperative day; RBC, red blood cell; RR, relative risk; TVE, total vascular exclusion; benign liver tumor; cavernous hemangioma; hepatectomy; vascular tumor of the liver.
© 2020 Indian National Association for Study of the Liver. Published by Elsevier B.V.
Similar articles
-
Surgery for symptomatic hepatic hemangioma: Resection vs. enucleation, an experience over two decades.Ann Hepatobiliary Pancreat Surg. 2023 Aug 31;27(3):258-263. doi: 10.14701/ahbps.22-130. Epub 2023 May 2. Ann Hepatobiliary Pancreat Surg. 2023. PMID: 37127398 Free PMC article.
-
Surgical Management of Giant Hepatic Hemangioma: Single Center's Experience with 144 Patients.J Gastrointest Surg. 2018 May;22(5):849-858. doi: 10.1007/s11605-018-3696-y. Epub 2018 Feb 27. J Gastrointest Surg. 2018. PMID: 29488123
-
Giant cavernous liver hemangiomas: effect of operative approach on outcome.Arch Surg. 2004 Aug;139(8):818-21; discussion 821-3. doi: 10.1001/archsurg.139.8.818. Arch Surg. 2004. PMID: 15302689
-
Giant cavernous liver hemangiomas: is it the time to change the size categories?Hepatobiliary Pancreat Dis Int. 2016 Feb;15(1):21-9. doi: 10.1016/s1499-3872(15)60035-2. Hepatobiliary Pancreat Dis Int. 2016. PMID: 26818540 Review.
-
Management of giant liver hemangiomas: an update.Expert Rev Gastroenterol Hepatol. 2013 Mar;7(3):263-8. doi: 10.1586/egh.13.10. Expert Rev Gastroenterol Hepatol. 2013. PMID: 23445235 Review.
Cited by
-
The surgical outcomes and risk factors of giant hepatic haemangiomas: a single centre experience.BMC Surg. 2022 Jul 17;22(1):278. doi: 10.1186/s12893-022-01721-w. BMC Surg. 2022. PMID: 35843944 Free PMC article.
-
Practical approach to diagnose and manage benign liver masses.Hepatol Commun. 2024 Oct 30;8(11):e0560. doi: 10.1097/HC9.0000000000000560. eCollection 2024 Nov 1. Hepatol Commun. 2024. PMID: 39470338 Free PMC article. Review.
-
Response to "Revisiting the Surgical Management of Gi ant Hepatic Hemangiomas: Enucleation Versus Anatomical Resection?" by Rajakannu et al.J Clin Exp Hepatol. 2022 Mar-Apr;12(2):718. doi: 10.1016/j.jceh.2021.07.007. Epub 2021 Jul 16. J Clin Exp Hepatol. 2022. PMID: 35535084 Free PMC article. No abstract available.
-
Enucleation versus hepatectomy for hepatic hemangiomas: A meta-analysis.Front Surg. 2022 Jul 28;9:960768. doi: 10.3389/fsurg.2022.960768. eCollection 2022. Front Surg. 2022. PMID: 35965862 Free PMC article. Review.
-
Benign liver tumours: understanding molecular physiology to adapt clinical management.Nat Rev Gastroenterol Hepatol. 2022 Nov;19(11):703-716. doi: 10.1038/s41575-022-00643-5. Epub 2022 Jul 14. Nat Rev Gastroenterol Hepatol. 2022. PMID: 35835851 Review.
References
-
- Ishak K.G., Rabin L. Benign tumors of the liver. Med Clin. 1975;59:995–1013. - PubMed
-
- Di Biscegli A.M., Befeler A.S. Tumors and cysts of the liver. In: Feldman M., Friedman L.S., Brandt L.J., editors. Gastrointestinal and Liver Disease. Saunders Elseiver; Philadelphia: 2010. pp. 1586–1587.
-
- Farges O., Daradkeh S., Bismuth H. Cavernous hemangiomas of the liver: are there any indications for resection? World J Surg. 1995;19:19–24. - PubMed
-
- Hoekstra L.T., Bieze M., Erdogan D., Roelofs J.J., Beuers U.H., van Gulik T.M. Management of giant liver hemangiomas: an update. Expet Rev Gastroenterol Hepatol. 2013;7:263–268. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials